COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
PolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin
PolyPeptide Group announces strong H1 2026 results: +42% revenue growth and improved EBITDA margin. 2026 full-year guidance raised to 25-30% growth and high-teens EBITDA margin -
-
-
COMMUNIQUÉ DE PRESSE
PolyPeptide Group: Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
Samsung Biologics announces tender offer to acquire PolyPeptide Group AG at CHF 44.31 per share, reflecting growth and profitability. PolyPeptide reports marked acceleration in H1 2026 results -
-
-
